{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:00:40Z","timestamp":1792130440225,"version":"4.4.0"},"reference-count":66,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Faricimab is the first and only bispecific antibody approved by the U.S. Food and Drug Administration (FDA) for intravitreal injection. Given its increasingly widespread use in retinal vascular diseases, understanding its adverse events (AEs) in real-world settings is crucial. This study employed the FDA Adverse Event Reporting System (FAERS) database to investigate potential safety concerns, with the aim of providing new insights for clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study conducted a disproportionality analysis of adverse event data from the FAERS database, in which faricimab was identified as the primary suspect, covering the period from the first quarter of 2022 to the second quarter of 2024. To ensure the accuracy and reliability of the study, we employed four types of disproportionality analyses: the reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), and Bayesian confidence propagation neural network (BCPNN). Additionally, the Weibull distribution was utilized to model the risk of adverse events over time.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 2,735 adverse reaction reports, in which faricimab was identified as the primary suspect, were retrieved from the FAERS database. The analysis showed that faricimab-induced AEs occurred across 25 system organ classes (SOCs), with eye disorders meeting the positive threshold for all four algorithms. Significant AEs were mapped to preferred terms (PT), identifying the adverse reactions listed on the drug label: endophthalmitis, elevated intraocular pressure, cataract, retinal pigment epithelial tear, vitreous floaters, retinal vasculitis, retinal artery occlusion, and retinal vein occlusion. In addition to the AEs listed on the drug label, several previously unreported AEs were identified, including blindness, cerebral infarction, retinal hemorrhage, retinal occlusive vasculitis, glaucoma, dry eye, metamorphopsia, and unilateral blindness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study provided valuable evidence on the real-world safety of faricimab, suggesting that clinicians should place greater emphasis on monitoring its adverse effects during use.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1521358","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:59:04Z","timestamp":1741766344000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Adverse event reporting of faricimab: a disproportionality analysis of FDA adverse event reporting system (FAERS) database"],"prefix":"10.3389","volume":"16","author":[{"given":"Chang-Zhu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fu-Li","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun-Qiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/abt\/tbz008","article-title":"Effect of allotypic variation of human IgG1 on the thermal stability of disulfide-linked knobs-into-holes mutants of the Fc for stable bispecific antibody design","volume":"2","author":"Akiba","year":"2019","journal-title":"Antib. Ther."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1038\/s41433-024-03079-0","article-title":"Intraocular inflammation with faricimab: insights from manufacturer and user facility device experience (MAUDE) database","volume":"38","author":"Alkhawaldeh","year":"2024","journal-title":"Eye (Lond)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1167\/iovs.62.9.9","article-title":"Diabetes exacerbates the intraocular pressure-independent retinal ganglion cells degeneration in the DBA\/2J model of glaucoma","volume":"62","author":"Amato","year":"2021","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"5397","DOI":"10.2147\/DDDT.S86269","article-title":"Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis","volume":"9","author":"Ba","year":"2015","journal-title":"Drug Des. Devel Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ajo.2024.08.008","article-title":"Severe intraocular inflammation after intravitreal injection of faricimab: a single-site case series of six patients","volume":"269","author":"Ben Ghezala","year":"2024","journal-title":"Am. J. Ophthalmol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3390\/cancers14010022","article-title":"Venetoclax in relapsed\/refractory acute myeloid leukemia: are supporting evidences enough?","volume":"14","author":"Brancati","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","article-title":"One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration","volume":"13","author":"Cancian","year":"2024","journal-title":"Ophthalmol. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1080\/09273948.2024.2361834","article-title":"Intra-ocular inflammation and occlusive retinal vasculitis following intravitreal injections of faricimab: a case report","volume":"32","author":"Chen","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B10","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3390\/ijms19010237","article-title":"Anesthetic preconditioning as endogenous neuroprotection in glaucoma","volume":"19","author":"Chou","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1159\/000529930","article-title":"Old problem in a new guise: retinal pigment epithelium tear after intravitreal faricimab (Vabysmo(\u00ae)) injection","volume":"14","author":"Clemens","year":"2023","journal-title":"Case Rep. Ophthalmol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"824885","DOI":"10.3389\/fphar.2021.824885","article-title":"Caffeine protects against retinal inflammation","volume":"12","author":"Conti","year":"","journal-title":"Front. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"705405","DOI":"10.3389\/fphar.2021.705405","article-title":"Brimonidine is neuroprotective in animal paradigm of retinal ganglion cell damage","volume":"12","author":"Conti","year":"","journal-title":"Front. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.3390\/jcm12144674","article-title":"Exploring the relationship between anti-VEGF therapy and glaucoma: implications for management strategies","volume":"12","author":"Daka","year":"2023","journal-title":"J. Clin. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/pharmaceutics15051413","article-title":"Faricimab for the treatment of diabetic macular edema and neovascular age-related macular degeneration","volume":"15","author":"Ferro Desideri","year":"2023","journal-title":"Pharmaceutics"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","article-title":"Clinical pharmacology of intravitreal anti-VEGF drugs","volume":"32","author":"Fogli","year":"2018","journal-title":"Eye (Lond)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/healthcare11101479","article-title":"Severe gastrointestinal toxicity following the use of gilteritinib: a case series and analysis of postmarketing surveillance data","volume":"11","author":"Gozzo","year":"2023","journal-title":"Healthc. (Basel)"},{"key":"B19","doi-asserted-by":"publisher","first-page":"748766","DOI":"10.3389\/fphar.2021.748766","article-title":"Off-label use of venetoclax in patients with acute myeloid leukemia: single center experience and data from pharmacovigilance database","volume":"12","author":"Gozzo","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/08820538.2014.959616","article-title":"Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications","volume":"29","author":"Haddock","year":"2014","journal-title":"Semin. Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-030-66014-7_1","article-title":"Age-related macular degeneration: epidemiology and clinical aspects","volume":"1256","author":"Keenan","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/jamaophthalmol.2020.2699","article-title":"Efficacy of every four monthly and quarterly dosing of faricimab vs ranibizumab in neovascular age-related macular degeneration: the STAIRWAY phase 2 randomized clinical trial","volume":"138","author":"Khanani","year":"2020","journal-title":"JAMA Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"102091","DOI":"10.1016\/j.clae.2023.102091","article-title":"Platelet-rich plasma for treating dry eye disease - a systematic review and meta-analysis","volume":"47","author":"Kwaku Akowuah","year":"2024","journal-title":"Cont. Lens Anterior Eye"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.2147\/OPTH.S136500","article-title":"The effect of intravitreal injections on dry eye, and proposed management strategies","volume":"11","author":"Laude","year":"2017","journal-title":"Clin. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"9424","DOI":"10.3390\/ijms23169424","article-title":"Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review","volume":"23","author":"Liberski","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e36370","DOI":"10.1097\/MD.0000000000036370","article-title":"Comparative efficacy and safety of Faricimab and other anti-VEGF therapy for age-related macular degeneration and diabetic macular edema: a systematic review and meta-analysis of randomized clinical trials","volume":"102","author":"Li","year":"2023","journal-title":"Med. Baltim."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1111\/jdi.13480","article-title":"Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy","volume":"12","author":"Lin","year":"2021","journal-title":"J. Diabetes Investig."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1017889","DOI":"10.3389\/fphar.2022.1017889","article-title":"Ocular adverse events associated with anti-VEGF therapy: a pharmacovigilance study of the FDA adverse event reporting system (FAERS)","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/IAE.0b013e31820a67e4","article-title":"Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies","volume":"31","author":"Mccannel","year":"2011","journal-title":"Retina"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9S","year":"2021","journal-title":"Ophthalmology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10384-023-00985-w","article-title":"Efficacy, durability, and safety of faricimab up to every 16 weeks in patients with neovascular age-related macular degeneration: 1-year results from the Japan subgroup of the phase 3 TENAYA trial","volume":"67","author":"Mori","year":"2023","journal-title":"Jpn. J. Ophthalmol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1038\/s41598-024-62559-1","article-title":"One-year outcomes and safety assessment of faricimab in treatment-na\u00efve patients with neovascular age-related macular degeneration in Japan","volume":"14","author":"Mukai","year":"2024","journal-title":"Sci. Rep."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1080\/09273948.2023.2293925","article-title":"Uveitis following intravitreal injections of faricimab: a case report","volume":"32","author":"Palmieri","year":"2024","journal-title":"Ocul. Immunol. Inflamm."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies","volume":"17","author":"Panos","year":"2023","journal-title":"Drug Des. Devel Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.3390\/molecules26154673","article-title":"Lipid nanoparticles traverse non-corneal path to reach the posterior eye segment: in vivo evidence","volume":"26","author":"Puglia","year":"2021","journal-title":"Molecules"},{"key":"B37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12348-024-00429-7","article-title":"Occlusive retinal vasculitis associated with intravitreal Faricimab injections","volume":"14","author":"Reichel","year":"2024","journal-title":"J. Ophthalmic Inflamm. Infect."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.3390\/pharmaceutics15051370","article-title":"Fluoxetine protects retinal ischemic damage in mice","volume":"15","author":"Romano","year":"2023","journal-title":"Pharmaceutics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1063625","DOI":"10.3389\/fphar.2022.1063625","article-title":"Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System","volume":"13","author":"Sakai","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41433-019-0670-1","article-title":"Faricimab: expanding horizon beyond VEGF","volume":"34","author":"Sharma","year":"2020","journal-title":"Eye (Lond)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1080\/14712598.2024.2336087","article-title":"Global experience of faricimab in clinical settings - a review","volume":"24","author":"Sharma","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1177\/24741264241253899","article-title":"Faricimab-associated retinal vasculitis","volume":"8","author":"Siddiqui","year":"2024","journal-title":"J. Vitr. Dis."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.2147\/DDDT.S307657","article-title":"Cytokine and chemokine profile changes in patients with neovascular age-related macular degeneration after intravitreal ranibizumab injection for choroidal neovascularization","volume":"15","author":"Sun","year":"2021","journal-title":"Drug Des. Devel Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1592\/phco.24.13.1099.38090","article-title":"Pharmacovigilance in the 21st century: new systematic tools for an old problem","volume":"24","author":"Szarfman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"B46","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1001\/jamaophthalmol.2024.0530","article-title":"Severe intraocular inflammation following intravitreal faricimab","volume":"142","author":"Thangamathesvaran","year":"2024","journal-title":"JAMA Ophthalmol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.4103\/0976-500X.120947","article-title":"Anti-vascular endothelial growth factor drugs safety and efficacy in ophthalmic diseases","volume":"4","author":"Ventrice","year":"2013","journal-title":"J. Pharmacol. Pharmacother."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1408135","DOI":"10.3389\/fphar.2024.1408135","article-title":"A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Wang","year":"","journal-title":"Front. Pharmacol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1404658","DOI":"10.3389\/fphar.2024.1404658","article-title":"The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database","volume":"15","author":"Wang","year":"","journal-title":"Front. Pharmacol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1007\/s12325-023-02675-y","article-title":"Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis","volume":"40","author":"Watkins","year":"2023","journal-title":"Adv. Ther."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/IAE.0000000000001018","article-title":"Dynamic changes of the another chamber angle produced by intravitreal anti-vascular growth factor injections","volume":"36","author":"Wen","year":"2016","journal-title":"Retina"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1167\/iovs.16-20786","article-title":"Intravitreal anti-VEGF injections reduce aqueous outflow facility in patients with neovascular age-related macular degeneration","volume":"58","author":"Wen","year":"2017","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41433-024-03209-8","article-title":"Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE)","volume":"39","author":"Wijesingha","year":"2024","journal-title":"Eye (Lond)."},{"key":"B54","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/OPTH.S232548","article-title":"Incidence of glaucoma or ocular hypertension after repeated anti-vascular endothelial growth factor injections for macular degeneration","volume":"13","author":"Wingard","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.3390\/jcm13154508","article-title":"Short-term clinical outcomes of patients with diabetic macular edema following a therapy switch to faricimab","volume":"13","author":"Wolfrum","year":"2024","journal-title":"J. Clin. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1080\/14740338.2024.2322712","article-title":"Adverse events associated with brolucizumab: a disproportionality analysis of the FDA adverse event reporting system (FAERS)","volume":"23","author":"Xiong","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"B59","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ophtha.2024.07.008","article-title":"Cardiovascular and cerebrovascular adverse events associated with intravitreal anti-VEGF monoclonal antibodies: a world health organization pharmacovigilance study","volume":"132","author":"Yang","year":"2025","journal-title":"Ophthalmology"},{"key":"B60","doi-asserted-by":"publisher","first-page":"eabj2177","DOI":"10.1126\/scitranslmed.abj2177","article-title":"Targeting C3b\/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy","volume":"14","author":"Yang","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"e00897","DOI":"10.1002\/prp2.897","article-title":"Evaluation of cardiac parameters and other safety outcomes of brolucizumab treatment in patients with neovascular age-related macular degeneration","volume":"10","author":"Zakaria","year":"2022","journal-title":"Pharmacol. Res. Perspect."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/j.ophtha.2024.05.025","article-title":"Efficacy of faricimab versus aflibercept in diabetic macular edema in the 20\/50 or worse vision subgroup in phase III YOSEMITE and RHINE trials","volume":"131","author":"Zarbin","year":"2024","journal-title":"Ophthalmology"},{"key":"B63","doi-asserted-by":"publisher","first-page":"107335","DOI":"10.1016\/j.phrs.2024.107335","article-title":"Comprehensive assessment of the impact of intravitreal faricimab on retinal diseases: a systematic review, meta-analysis, and trial sequential analysis","volume":"208","author":"Zhang","year":"2024","journal-title":"Pharmacol. Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12959-022-00427-6","article-title":"Vascular endothelial growth factor and the risk of venous thromboembolism: a genetic correlation and two-sample Mendelian randomization study","volume":"20","author":"Zhang","year":"2022","journal-title":"Thromb. J."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1393940","DOI":"10.3389\/fphar.2024.1393940","article-title":"Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system","volume":"15","author":"Zhao","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s12886-021-02003-4","article-title":"Short- and long-term agreement and reproducibility of 48-hours intraocular pressure measurements in glaucoma patients","volume":"21","author":"Zimmermann","year":"2021","journal-title":"BMC Ophthalmol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1521358\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:59:07Z","timestamp":1741766347000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1521358\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":66,"alternative-id":["10.3389\/fphar.2025.1521358"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1521358","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1521358"}}